METHOD OF ESTIMATING EFFICACY OF VASCULAR THERAPY BY ENDOTHELIAL DYSFUNCTION INTENSITY Russian patent published in 2012 - IPC G01N33/49 A61P9/10 

FIELD: medicine.

SUBSTANCE: before the drug prescription and during the therapeutic progression, patient's peripheral venous blood is sampled, ultracentrifuged to recover endotheliocytes to be incubated with PTS-marked annexin-V. It is followed by endotheliocyte count with using an immersion microscope in 10 vision fields and the prevailing content of annexin-V negative endotheliocytes prevailing over annexin-V positive endotheliocytes enables stating the low involvement of vascular endothelium in the pathological process or the efficacy of vascular therapy; annexin-V positive endotheliocytes prevailing over annexin-V negative endotheliocytes makes it possible to state the high involvement of the endothelium in the pathological process or the inefficacy of vascular therapy: normal average number of circulating endotheliocytes 1-3, annexin-V positive - 0; in degree 1 endothelial dysfunction, the number of circulating endotheliocytes 4-6 wherein 1-3 - annexin-V positive; in degree 2 endothelial dysfunction, the number of circulating endotheliocytes 7-12 wherein 4-6 annexin-V positive; in degree 3 endothelial dysfunction, the number of circulating endotheliocytes 13-18 wherein annexin-V positive 7-10; in degree 4 endothelial dysfunction, the number of circulating endotheliocytes 19-25, annexin-V positive 12-24, in critical endothelial dysfunction with a high risk of cardiovascular complications, the number of circulating endotheliocytes more than 25, all of them are annexin-V positive.

EFFECT: use of the declared method enables the proved selection of the therapeutic agents and their doses improving a morphological and functional condition of the vascular endothelial cells that reduces a risk of the onset and the progression of endothelial dysfunction and the development of a severe vascular pathology.

2 ex, 2 dwg